{
  "id": 20389030,
  "title": "Hanmi Drugs Show Promise in Phase 1 Trials",
  "url": "https://urgent.news/2026/11/17/hanmi-drugs-show-promise-in-phase-1-trials",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-17T06:16:51.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=281511"
  },
  "original_language": "en",
  "account": "Hanmi Pharmaceutical's next-generation anticancer drugs, HM97662 and BH3120, showed promise in Phase 1 clinical trials, according to data presented at the ESMO Congress 2026 in Madrid, Spain. HM97662 uses a dual-inhibition approach targeting EZH1 and EZH2 proteins to suppress gene expression, overcoming resistance that can arise from inhibiting only EZH2. The trial revealed a manageable safety profile and notable antitumor activity in specific mutation groups, including ovarian clear cell carcinoma, chordoma, mesothelioma, and uterine sarcoma. BH3120, an immuno-oncology candidate, employs a bispecific antibody platform to target cancer cells and activate immune cells, potentially expanding treatment to various solid tumors. With favorable liver toxicity results, the drug showed positive safety in a dose-escalation study involving 45 patients. Hanmi Pharmaceutical plans to conduct further evaluations in an upcoming dose-expansion stage.",
  "summary": "Hanmi Pharmaceutical said two next-generation anticancer drug candidates under development demonstrated both antitumor activity and safety in global Phase 1 clinical trials. The data, disclosed at the ESMO Congress 2026 held in Madrid, Spain, from on Oct. 23 to 27, provide specific clinical evidence",
  "key_points": [
    "Hanmi's HM97662 and BH3120 showed promise in Phase 1 trials.",
    "HM97662 targets EZH1 and EZH2 proteins to suppress gene expression.",
    "BH3120 is an immuno-oncology candidate with positive liver toxicity results."
  ],
  "editors_take": "Targeting specific protein mutations and leveraging bispecific antibody platforms allows Hanmi to bypass common resistance mechanisms and broaden the potential therapeutic reach for diverse solid tumor types.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}